Adial Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/16/22
Adial Pharmaceuticals Announces Topline Results For Onward™ Phase 3 Trial for AD04 in Patients with Alcohol Use DisorderGlobeNewsWire • 07/20/22
Adial Pharmaceuticals to Announce Topline Results of ONWARD™ Phase 3 Trial for AD04 in Patients With Alcohol Use DisorderGlobeNewsWire • 07/18/22
Twin Vee PowerCats Co.'s Board of Directors Appoints Kevin Schuyler as Newest DirectorAccesswire • 07/07/22
Adial Pharmaceuticals Provides Letter to Shareholders From CEO William StilleyGlobeNewsWire • 06/28/22
Adial Pharmaceuticals Announces Database Lock for the ONWARD™ Phase 3 Clinical TrialGlobeNewsWire • 06/27/22
Adial Pharmaceuticals Awarded Additional U.S. Patent Combining the Use of the Company's Proprietary Genetic Diagnostic With AD04 to Treat Alcohol and Drug DependenceGlobeNewsWire • 06/14/22
Adial Pharmaceuticals Announces Research Collaboration with the Medical College of Wisconsin to Advance Purnovate's Adenosine Compounds as Potential Treatments for Diabetes and NASHGlobeNewsWire • 05/19/22
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/16/22
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate's Adenosine Compounds as Potential Treatments for Inflammatory Diseases & DisordersGlobeNewsWire • 05/04/22
Adial Pharmaceuticals CEO to Participate in a Fireside Chat at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28thGlobeNewsWire • 03/22/22
Adial Pharmaceuticals Announces Completion of Last Patient, Last Visit in its ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with Alcohol Use DisorderGlobeNewsWire • 02/24/22
Adial Pharmaceuticals Announces Pricing of $10 Million Registered Direct OfferingGlobeNewsWire • 02/11/22
Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate's PNV-5032 as a Potential Treatment for AsthmaGlobeNewsWire • 02/09/22
Adial Pharmaceuticals Receives Notice of Allowance on U.S. Patent for the Treatment for Opioid Use Disorder Using AD04GlobeNewsWire • 01/24/22
Is Adial Pharmaceuticals, Inc. (ADIL) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/12/22
Adial Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2022 ConferenceGlobeNewsWire • 01/10/22
Adial Pharmaceuticals Completes Private Placement of Common Stock at $4.00 Per ShareGlobeNewsWire • 12/22/21
Adial Announces Cary J. Claiborne, a Renowned Pharmaceutical Executive and Current Board Member, has Joined the Company as Chief Operating OfficerGlobeNewsWire • 12/08/21
Adial Pharmaceuticals Announces Positive Pre-Clinical Data for PNV2 as a Drug Candidate for Triple Negative Breast CancerGlobeNewsWire • 11/29/21
REMINDER: Adial Pharmaceuticals to Host Conference Call Thursday, November 18, 2021 at 11:00AM Eastern to Provide Clinical Update and Discuss Latest DevelopmentsGlobeNewsWire • 11/17/21
Adial Pharmaceuticals Announces Private Placement of Common Stock at $4.00 Per Share and Cash Exercise of Stock OptionsGlobeNewsWire • 11/10/21